Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias

Cerri, S; Siani, F; Blandini, F

Blandini, F (reprint author), C Mondino Natl Neurol Inst, Ctr Res Neurodegenerat Dis, Via Mondino 2, I-27100 Pavia, Italy.

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017; 26 (7): 777

Abstract

Introduction: Prolonged treatment of Parkinson's disease (PD) with levodopa (L-DOPA) results in motor complications, including motor fluctuations and ......

Full Text Link